^
    1m
    Exploring the efficacy and safety of famitinib combined with epalrestat and torivirine in the treatment of advanced and recurrent/metastatic cervical cancer (ChiCTR2500111354)
    P2, N=90, Not yet recruiting, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    famitinib (SHR 1020) • iparomlimab (QL1604)
    1m
    A prospective, multicenter, phase II study of famitinib maleate combined with camrelizumab and chemotherapy as neoadjuvant therapy for locally advanced cervical cancer. (ChiCTR2500109134)
    P2, N=60, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New P2 trial
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    2ms
    A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. (clinicaltrials.gov)
    P3, N=48, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=560 --> 48 | Trial completion date: Oct 2023 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Aug 2025; Terminated by Sponsor
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    carboplatin • AiRuiKa (camrelizumab) • pemetrexed • famitinib (SHR 1020)
    3ms
    Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=443, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Apr 2025 --> May 2027
    Trial completion date
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    3ms
    CASTLE-ZS-03: Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Fudan University
    New P2 trial
    |
    retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
    3ms
    A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    3ms
    A Study of SHR-1802 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P2, N=25, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=124 --> 25 | Recruiting --> Terminated; Adjustment of R&D strategy
    Enrollment change • Trial termination
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802
    3ms
    FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
    P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Sep 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
    |
    Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Yidafan (ivonescimab) • AiRuiLi (adebrelimab) • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
    4ms
    A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=194, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Jul 2025 | Trial primary completion date: Dec 2022 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • pemetrexed • famitinib (SHR 1020)
    4ms
    Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance. (PubMed, Pharmaceutics)
    Sunitinib, regorafenib, and ripretinib are currently approved as standard second-, third-, and fourth-line therapies, each demonstrating efficacy against distinct mutational profiles. Avapritinib, notably effective against PDGFRA D842V mutations, represents a milestone for previously untreatable subgroups. Several alternative agents-such as nilotinib, masitinib, sorafenib, dovitinib, pazopanib, and ponatinib-have shown varying degrees of success in refractory cases or specific genotypes. Investigational compounds, including crenolanib, bezuclastinib, famitinib, motesanib, midostaurin, IDRX-42, and olverembatinib, are under development to address resistant or wild-type GISTs...Future strategies include precision medicine approaches such as ctDNA-guided therapy, rational drug combinations, and novel drug delivery systems to optimize bioavailability and reduce toxicity. Ongoing research will be crucial for refining treatment sequencing and expanding therapeutic options, especially for rare GIST subtypes.
    Review • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    sorafenib • imatinib • sunitinib • Iclusig (ponatinib) • pazopanib • Tasigna (nilotinib) • Stivarga (regorafenib) • midostaurin • crenolanib (ARO-002) • Ayvakit (avapritinib) • Nailike (olverembatinib) • Qinlock (ripretinib) • dovitinib (TKI258) • famitinib (SHR 1020) • motesanib (AMG 706) • GSK6042981 • bezuclastinib (PLX9486) • Kinaction (masitinib)
    6ms
    Neoadjuvant SNF Precision Therapy Phase III (clinicaltrials.gov)
    P3, N=404, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiTan (rivoceranib) • AiRuiYi (fluzoparib) • famitinib (SHR 1020) • AiRuiLi (adebrelimab)
    8ms
    Neoadjuvant SNF Precision Therapy Phase III (clinicaltrials.gov)
    P3, N=404, Not yet recruiting, Fudan University
    New P3 trial
    |
    AiTan (rivoceranib) • AiRuiYi (fluzoparib) • famitinib (SHR 1020) • AiRuiLi (adebrelimab)